{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:36:21Z","timestamp":1773419781576,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.jocd.2012.11.004","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T02:02:29Z","timestamp":1359597749000},"page":"22-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Bone Turnover Markers in Primary Hyperparathyroidism"],"prefix":"10.1016","volume":"16","author":[{"given":"Aline G.","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8182","key":"10.1016\/j.jocd.2012.11.004_bib1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(80)91783-3","article-title":"Primary hyperparathyroidism: changes in the pattern of clinical presentation","volume":"1","author":"Mundy","year":"1980","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jocd.2012.11.004_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/jbmr.5650100917","article-title":"Bone structure in post hyperparathyroid, osteoporotic, and normal women","volume":"10","author":"Parisien","year":"1995","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2004.01422.x","article-title":"Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features","volume":"257","author":"Bilezikian","year":"2005","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jocd.2012.11.004_bib4","series-title":"Dynamics of Bone and Cartilage Metabolism","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/B9-78-012088-5\/62650-0364","article-title":"Validation of biochemical markers of bone turnover","author":"Brixen","year":"2006"},{"key":"10.1016\/j.jocd.2012.11.004_bib5","first-page":"399","article-title":"Molecular markers of bone metabolism in parathyroid disease","volume":"Vol. 1","author":"Seibel","year":"2001"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","article-title":"Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices","volume":"14","author":"Woitge","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1373\/clinchem.2003.029355","article-title":"Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis)","volume":"50","author":"Alatalo","year":"2004","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.jocd.2012.11.004_bib8","first-page":"3487","article-title":"Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"81","author":"Guo","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S8756-3282(97)00078-1","article-title":"Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients","volume":"21","author":"Christiansen","year":"1997","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jocd.2012.11.004_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2796.1998.00241.x","article-title":"Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease","volume":"243","author":"Valdemarsson","year":"1998","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.jocd.2012.11.004_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(99)00150-7","article-title":"Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy","volume":"25","author":"Christiansen","year":"1999","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.jocd.2012.11.004_bib12","first-page":"723","article-title":"Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism","volume":"80","author":"Silverberg","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jocd.2012.11.004_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop","volume":"94","author":"Bilezikian","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jocd.2012.11.004_bib14","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0039-6060(97)90328-7","article-title":"Changes in bone mass and serum markers of bone metabolism after parathyroidectomy","volume":"122","author":"Thorsen","year":"1997","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S8756-3282(00)00260-X","article-title":"Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment","volume":"26","author":"Steiniche","year":"2000","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2265.1995.tb02668.x","article-title":"Changes in bone mass and metabolism after surgery for primary hyperparathyroidism","volume":"42","author":"Garton","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jocd.2012.11.004_bib18","first-page":"640","article-title":"The usefulness of high preoperative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy","volume":"35","author":"Alonso","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.jocd.2012.11.004_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00774-007-0754-z","article-title":"Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study","volume":"25","author":"Tamura","year":"2007","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"10.1016\/j.jocd.2012.11.004_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00774-008-0033-7","article-title":"Potential utility of high preoperative levels\u00a0of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy","volume":"27","author":"Boudou","year":"2009","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1420451","article-title":"Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism","volume":"142","author":"Guo","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.jocd.2012.11.004_bib22","first-page":"3450","article-title":"Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption\u2014a clinical research center study","volume":"81","author":"Grey","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jocd.2012.11.004_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00223-002-2100-8","article-title":"Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism","volume":"73","author":"Stilgren","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"53","key":"10.1016\/j.jocd.2012.11.004_bib24","doi-asserted-by":"crossref","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","article-title":"Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways","volume":"285","author":"Krause","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"20","key":"10.1016\/j.jocd.2012.11.004_bib25","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"29","key":"10.1016\/j.jocd.2012.11.004_bib26","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1359\/jbmr.061002","article-title":"Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation","volume":"22","author":"van Bezooijen","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.jocd.2012.11.004_bib28","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1210\/jc.2011-0566","article-title":"Circulating sclerostin in disorders of parathyroid gland function","volume":"96","author":"Costa","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.jocd.2012.11.004_bib30","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00198-011-1806-8","article-title":"Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study","volume":"23","author":"Ardawi","year":"2012","journal-title":"Osteoporos Int"},{"issue":"7749","key":"10.1016\/j.jocd.2012.11.004_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(72)90173-0","article-title":"Treatment with oestrogens of\u00a0primary hyperparathyroidism in post-menopausal women","volume":"1","author":"Gallagher","year":"1972","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/0003-4819-100-5-633","article-title":"Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism","volume":"100","author":"Marcus","year":"1984","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.jocd.2012.11.004_bib33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198606053142304","article-title":"Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women","volume":"314","author":"Selby","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jocd.2012.11.004_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.jocd.2012.11.004_bib35","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women","volume":"160","author":"Orr-Walker","year":"2000","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.jocd.2012.11.004_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01623394","article-title":"Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report","volume":"6","author":"Diamond","year":"1996","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2007.03162.x","article-title":"Primary hyperparathyroidism and the skeleton","volume":"69","author":"Mosekilde","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","article-title":"Raloxifene reverses bone loss in\u00a0postmenopausal women with mild asymptomatic primary hyperparathyroidism","volume":"16","author":"Zanchetta","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.jocd.2012.11.004_bib39","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.jocd.2012.11.004_bib40","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jocd.2012.11.004_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MAJ.0b013e3181379f3e","article-title":"Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy","volume":"335","author":"Iglesias","year":"2008","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.jocd.2012.11.004_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","article-title":"Cinacalcet for the treatment of primary hyperparathyroidism","volume":"57","author":"Sajid-Crockett","year":"2008","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.jocd.2012.11.004_bib44","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib45","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jocd.2012.11.004_bib46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.jocd.2012.11.004_bib47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/j.1552-4604.1977.tb04624.x","article-title":"Metabolic effects of diphosphonate in primary hyperparathyroidism","volume":"17","author":"Kaplan","year":"1977","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-95-1-23","article-title":"Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism","volume":"95","author":"Shane","year":"1981","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jocd.2012.11.004_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jocd.2012.11.004_bib50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.jocd.2012.11.004_bib51","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.jocd.2012.11.004_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.jocd.2012.11.004_bib53","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jocd.2012.11.004_bib54","first-page":"1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695012002338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695012002338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:37:20Z","timestamp":1761082640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695012002338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1094695012002338"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2012.11.004","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Turnover Markers in Primary Hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2012.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}